Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA: 688506)
China
· Delayed Price · Currency is CNY 201.36
+2.27 (1.14%)
Nov 21, 2024, 11:30 AM CST
Sichuan Biokin Pharmaceutical Co.,Ltd. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Net Income | 3,800 | -780.5 | -282.38 | -99.99 | 37.9 | 7.73 | Upgrade
|
| Depreciation & Amortization | 64.28 | 64.28 | 62.94 | 53.14 | 49.31 | 46.69 | Upgrade
|
| Other Amortization | 2.75 | 2.75 | 1.79 | 1.08 | 1.2 | 0.83 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.15 | -0.15 | 0.02 | -0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.29 | 0.29 | 0.46 | 6.13 | 0.9 | 4.3 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0 | -0 | - | -3.14 | -2.54 | -0.16 | Upgrade
|
| Provision & Write-off of Bad Debts | -6.65 | -6.65 | 7.58 | -3 | -2.02 | -3.67 | Upgrade
|
| Other Operating Activities | 434.83 | 40.74 | 27.79 | 9.45 | 9.6 | 6.07 | Upgrade
|
| Change in Accounts Receivable | 73.6 | 73.6 | -142.62 | 62.89 | 78.12 | 14.53 | Upgrade
|
| Change in Inventory | -52.56 | -52.56 | -23.96 | -22.22 | 10.44 | -9.19 | Upgrade
|
| Change in Accounts Payable | 35.92 | 35.92 | 107.12 | -121.61 | -92.57 | -29.5 | Upgrade
|
| Change in Other Net Operating Assets | -0.04 | -0.04 | 0.03 | -0.06 | -0.04 | 0.04 | Upgrade
|
| Operating Cash Flow | 4,359 | -615.35 | -258.65 | -135.03 | 78.46 | 27.99 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 180.30% | 112.85% | Upgrade
|
| Capital Expenditures | -69.01 | -81.94 | -34.56 | -44.6 | -15.37 | -21.04 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.04 | 0.06 | 0.01 | 0.07 | 0.03 | 0.02 | Upgrade
|
| Investment in Securities | -20.05 | -20.05 | - | 197.2 | - | - | Upgrade
|
| Other Investing Activities | -639.78 | 20.05 | - | 3.48 | -194.66 | 0.17 | Upgrade
|
| Investing Cash Flow | -728.8 | -81.88 | -34.55 | 156.15 | -210 | -20.85 | Upgrade
|
| Long-Term Debt Issued | - | 447.7 | 467.54 | 302 | 150 | 194.73 | Upgrade
|
| Long-Term Debt Repaid | - | -312.94 | -220.82 | -184.21 | -194.73 | -153.07 | Upgrade
|
| Net Debt Issued (Repaid) | 1,017 | 134.76 | 246.72 | 117.79 | -44.73 | 41.66 | Upgrade
|
| Issuance of Common Stock | - | - | 907.47 | - | - | - | Upgrade
|
| Common Dividends Paid | -31.18 | -18.77 | -12.59 | -26.97 | -9.96 | -30.08 | Upgrade
|
| Other Financing Activities | -10.97 | -25.14 | -2.19 | -2.16 | -10.06 | 3.07 | Upgrade
|
| Financing Cash Flow | 974.89 | 90.84 | 1,139 | 88.66 | -64.76 | 14.65 | Upgrade
|
| Foreign Exchange Rate Adjustments | -64.04 | -2.62 | 0.26 | -0.76 | -2.01 | 2.16 | Upgrade
|
| Net Cash Flow | 4,541 | -609 | 846.47 | 109.01 | -198.31 | 23.95 | Upgrade
|
| Free Cash Flow | 4,290 | -697.29 | -293.21 | -179.63 | 63.09 | 6.95 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | 807.17% | - | Upgrade
|
| Free Cash Flow Margin | 73.38% | -124.10% | -41.69% | -22.55% | 6.23% | 0.58% | Upgrade
|
| Free Cash Flow Per Share | 10.75 | -1.74 | -0.81 | -0.50 | 0.18 | 0.02 | Upgrade
|
| Cash Income Tax Paid | 267.41 | 48.98 | 36.6 | 101.05 | 127.36 | 148.75 | Upgrade
|
| Levered Free Cash Flow | 2,184 | -396 | -145.1 | -135.4 | 65.39 | - | Upgrade
|
| Unlevered Free Cash Flow | 2,205 | -380.58 | -131.05 | -129.97 | 70.12 | - | Upgrade
|
| Change in Net Working Capital | 312.53 | -125.18 | -44.92 | 39.88 | -49.27 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.